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DZNep inhibits H3K27me3 deposition and
delays retinal degeneration in the rd1 mice
Shijie Zheng1,2, Lirong Xiao1, Yu Liu3, Yujiao Wang1,2, Lin Cheng4, Junjun Zhang2, Naihong Yan1 and Danian Chen 1,2
Abstract
Retinitis pigmentosa (RP) is a group of inherited retinal degenerative diseases causing progressive loss of
photoreceptors. Numerous gene mutations are identiﬁed to be related with RP, but epigenetic modiﬁcations may also
be involved in the pathogenesis. Previous studies suggested that both DNA methylation and histone acetylation
regulate photoreceptor cell death in RP mouse models. However, the role of histone methylation in RP has never been
investigated. In this study, we found that trimethylation of several lysine sites of histone H3, including lysine 27
(H3K27me3), increased in the retinas of rd1 mice. Histone methylation inhibitor DZNep signiﬁcantly reduced the
calpain activity, delayed the photoreceptor loss, and improved ERG response of rd1 retina. RNA-sequencing indicated
that DZNep synergistically acts on several molecular pathways that regulate photoreceptor survival in rd1 retina,
including PI3K-Akt and photoreceptor differentiation pathways, revealing the therapeutic potential of DZNep for RP
treatment. PI3K-Akt pathway and H3K27me3 form a feedback loop in rd1 retina, thus PI3K inhibitor LY294002 reduces
phosphorylation of Ezh2 at serine 21 and enhances H3K27me3 deposition, and inhibiting H3K27me3 by DZNep can
activate PI3K-Akt pathway by de-repressing gene expression of PI3K subunits Pik3r1 and Pik3r3. These ﬁndings suggest
that histone methylation, especially H3K27me3 deposition is a novel mechanism and therapeutic target for retinal
degenerative diseases, similar to H3K27me3-mediated ataxia-telangiectasia in Atm−/− mouse.
Introduction
Retinitis pigmentosa (RP) is a group of inherited retinal
degenerative diseases characterized by a two-stage pro-
cess, in which the rod photoreceptors degenerate ﬁrst,
followed by cone cell degeneration1, 2. There are more
than 1.5 million RP patients worldwide3, 4. Unfortunately,
there has been no effective therapy available for RP right
now. Rd1 mice, one of the most commonly used RP
animal model, carry a loss-of-function mutation in the
rod-speciﬁc Pde6β gene, representing a subset of RP
patients3, 5, 6. Several mechanisms are involved in the
pathogenesis of rd1 retina, including apoptotic and non-
apoptotic cell death, cell-intrinsic factors, disrupted
intracellular Ca2+ homeostasis, and epigenetic modiﬁca-
tions7–11.
Epigenetic modiﬁcations, including DNA methylation,
histone acetylation, and methylation, affect gene expres-
sion but do not change DNA sequences. Recent studies
have also identiﬁed histone variants, microRNAs, and
long non-coding RNAs as critical epigenetic mechan-
isms12, 13. Epigenetic deregulation has been involved in a
variety of retinal diseases, including retinal ﬁbrosis, reti-
noblastoma, RP, age-related macular degeneration, and
diabetic retinopathy14–18. Rd1 retinas have high levels of
5-methyl cytosine11, inhibiting DNA methyltransferases
(DNMTs) in rd1 retinal explants can reduce photo-
receptor death19. Histone deacetylase-4 (HDAC4, class II
HDAC) overexpression prolongs rod survival in rd1
mice15. However excessive HDAC activation can also
induce photoreceptor degeneration, as inhibition of
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HDACs I/II activity in rd1 retinal explants strongly pre-
vents photoreceptor death10.
Histone methylation is catalyzed by histone methyl-
transferases (HMT), and can activate or suppress tran-
scription20–22. It has been reported that histone lysine
methylation is associated with retinal development23, 24.
Previously we reported that knocking out Bmi1 results in
extensive photoreceptor survival in rd1 retina25. Bmi1 is a
component of the polycomb repressive complex 1 (PRC1),
which compacts chromatin and represses gene expres-
sion26. We also reported that knocking out Ezh2 in
embryonic retinal progenitors results in progressive
photoreceptor degeneration27. Ezh2 is the core compo-
nent of the PRC2 and catalyzes the addition of methyl
groups to histone H3 at lysine 27 (H3K27), leading to
epigenetic silencing28. Our results indicate that both
PRC1 and PRC2 may play critical roles in RP pathogen-
esis. Ezh2 can also recruit DNMT3 which is upregulated
in rd1 retina, thus providing a direct link between two key
epigenetic repression systems (PRC2 and DNA methyla-
tion) in rd1 retina19, 29, 30.
Since Ezh2 is mainly expressed in embryonic retina24, 27,
31, we examined whether histone lysine methylation
changes in postnatal rd1 retinas. To our surprise, we
found that postnatal rd1 retina has higher histone lysine
trimethylation, and HMT inhibitor 3-deazaneplanocin A
(DZNep) actually delays the retinal degeneration. This
result is similar to the H3K27me3-mediated neurode-
generation and ataxia-telangiectasia in Atm−/− mouse32,
suggesting that HMT inhibition in wild type (wt) retinal
progenitors and postnatal rd1 retinal cells may have
opposite effects on photoreceptor survival. Our study
discovers a novel strategy to treat retinal degeneration.
Results
Rd1 retina has high levels of histone H3 trimethylation
including H3K27me3
Trimethylation of lysine residues of histone H3 can
regulate gene transcription33. We measured the pan-
trimethyllysine level of mouse retina at P0 (postnatal day
0) and P10 by Western blotting. The pan-trimethyllysine
levels increased about 20–30% in rd1 mice than wt con-
trols at P0 and P10 (Fig. 1a, b). To determine the lysine
trimethylation sites, we applied tandem mass tags (TMT)
labeling and lysine trimethylation afﬁnity enrichment,
followed by high-resolution liquid chromatography and
mass spectrometry (LC-MS/MS) to P10 retinas (Fig. 1c).
We had identiﬁed 6 sites in histone H3 that contain
higher levels of lysine trimethylation in rd1 retina. These
sites included H3K27, H3K36, H3.1K27, H3.1K36,
H3.1K37, and H3.1K79 (Table 1). Mammalian histone H3
has three major variants (H3.1, H3.2, and H3.3) and they
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Fig. 1 Expression of pan-trimethyllysine and H3K27me3 in wt and rd1 retina at P0 and P10. a Representative Western blots of indicated
protein of indicated age and genotypes. b The quantiﬁcation of pan-trimethyllysine levels relative to histone H3 of a. c High-resolution MS/MS
spectrum of H3K27me3 of P10 retinas. d The expression of global H3K27me3 in rd1 and wt retinas at P10. Error bars represent SD of measurements
from at least three animals and asterisks indicate signiﬁcant differences between retinas of wt and rd1 mice (*p < 0.05, **p < 0.01, t-test)
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have very similar amino acid sequences34. To further
conﬁrm this result, we assessed the global H3K27me3
level using EpiQuik global H3K27me3 quantiﬁcation kit
(Colorimetric), and found that H3K27me3 consistently
increases in rd1 retina at P10 (Fig. 1d). These results
suggested that histone H3 lysine trimethylation probably
is involved in the retinal degeneration.
DZNep inhibits retinal degeneration and improves visual
function of rd1 mice
In rd1mice, rod loss begins at P8, reaches its death peak
at about P14, and nearly all rods die before P21. Cone cells
can survive for another 1–2 months2, 5. To examine
whether histone H3 lysine trimethylation affects the sur-
vival of photoreceptors, we performed subretinal injection
of DZNep into wt and rd1 eyes. DZNep is an inhibitor of
S-adenosylmethionine-dependent methytransferase35,
and can reduce the protein levels of PRC2 componets36,
and induce apoptosis in dividing cancer cells but not in
normal cells36. However, it has not been reported whether
DZNep has any effects on post-mitotic dying neurons.
We injected three dosages (1.25 μg, 2.5 μg, and 5 μg) of
DZNep at three time points (P0, P4, and P8). After
injection, retinas were collected and analyzed at P21.
Histological analysis showed no effects of DZNep on the
thickness of outer nuclear layer (ONL) of wt retinas
(Fig. 2a, b), whereas DZNep protected rods in a dose and
time-dependent manner (Fig. 2c–f). Of the three dosages
injected at P0, 5 μg had the most protective effects
(Fig. 2c, d). Of three time points injected with 5 μg
DZNep, the injection at P0 had the most protective effects
(Fig. 2e, f). Therefore, injection of 5 μg DZNep at P0 was
used for all the subsequent experiments and injected
retinas were analyzed at P14 and P21. At P14, DZNep
treatment increased the ONL thickness of rd1 retinas
from 25.38 ± 6.48 μm to 43.21 ± 3.78 μm (Fig. 3a, b). At
P21, there was only one row of photoreceptors left (4.91 ±
1.15 μm) in rd1 retinas, but in DZNep-treated rd1 retinas
there were at least three rows of photoreceptors left
(12.73 ± 1.12 μm) (Fig. 3a, b). TUNEL labeling indicated
that DZNep reduced cell death signiﬁcantly, from 231.5 ±
61.6 cells/mm2 ONL to 133 ± 35.2 cells/mm2 ONL
(Fig. 3a, c) in P14 rd1 retinas. No TUNEL+ cells were
detected in the ONL of rd1 retinas at P21 (Fig. 3a).
Immunostaining conﬁrmed that the survived cells at ONL
were rhodopsin+ rods (Fig. 3a).
To test whether the survived rods had visual function,
both dark- and light-adapted electroretinogram (ERG)
were performed at P14 and P21 after DZNep treatment.
The amplitudes of the dark-adapted ERG a- and b-wave,
as well as light-adapted ERG a- and b-wave were both
signiﬁcantly preserved in the DZNep-treated rd1 eyes,
compared with that in PBS treated rd1 eyes at P14
(Fig. 3d–h). However, the amplitudes were almost unde-
tectable and did not differ signiﬁcantly between DZNep-
treated and PBS-treated rd1mice at P21 (data not shown).
These results indicated that DZNep treatment can delay
the rods death, and partially restore visual function of rd1
mice at P14.
DZNep inhibits Ezh2 protein level, H3K27me3 deposition,
and calpain activity in ex vivo retinal explants of rd1 mice
To understand how DZNep protects rd1 retina, we
employed an ex vivo retinal explant system. Four different
concentrations (0.1 μM, 0.5 μM, 1 μM, 1.5 μM) of DZNep
had been tested. Western blotting conﬁrmed that 0.1–1.0
μM DZNep can reduce the protein levels of both Ezh2
and H3K27me3 in the retinal explants, and 1.0 μM
DZNep had the strongest effect (Fig. 4a–c). Interestingly,
1.5 μM DZNep had no major effects on the protein levels
of Ezh2 and H3K27me3 (Fig. 4a–c). Therefore, we used 1
μM DZNep for the following ex vivo studies. Several
studies indicated that DZNep may be a global inhibitor of
methyltransferases37, not only suppressing Ezh2 and
H3K27me3 levels36, but also inhibiting H3K9me3 and
H3K79me3 formation38, 39. However, we had not found
any effects of DZNep on H3K9me3 and H3K79me3 levels
in our ex vivo retinal explant system (Fig. 4a, c).
Consistent with the in vivo results (Fig. 1d), H3K27me3
also increased in rd1ex vivo retinal explants, cultured
from P0 to P10 (P0+ 10) (Fig. 4d), and DZNep treatment
reduced it to wt level (Fig. 4d). Calpain is activated in rd1
Table 1 Identiﬁed sites of lysine trimethylation of histone H3 in rd1 retina
Protein Protein names Position Modiﬁed sequence rd1/wt Ratio
F8WI35 Histone H3 27 _K(tr)SAPSTGGVK_ 1.718832
F8WI35 Histone H3 36 _SAPSTGGVK(tr)KPHR_ 2.805843
P68433 Histone H3.1 27 _K(tr)SAPATGGVK_ 1.5685
P68433 Histone H3.1 36 _SAPATGGVK(tr)KPHR_ 2.091536
P68433 Histone H3.1 37 _K(tr)SAPATGGVK(tr)KPHR_ 2.103125
P68433 Histone H3.1 79 _EIAQDFK(tr)TDLR_ 1.401175
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retina, and reducing calpain activity can delay photo-
receptor degeneration9, 40. We measured calpain activities
using a calpain activity assay kit. Consistent with previous
reports, calpain activity was higher in rd1 P10 retinas and
(P0+ 10) retinal explants (Fig. 4e, f). DZNep treatment
signiﬁcantly suppressed its elevation in rd1 P0+ 10 ret-
inal explants (Fig. 4f). These results validated that ex vivo
explants can represent the pathogenesis of in vivo rd1
retina, like several previous studies10, 19, and suggested
that DZNep can protect rd1 retina by suppressing calpain
activity and H3K27me3 deposition, but not H3K9me3 or
H3K79me3.
Ezh2/H3K27me3 interacts with PI3K-Akt pathway in rd1
retina
To understand why H3K27me3 increased in rd1 retina
and further explore the mechanism of DZNep protection
on rd1 photoreceptors, we performed RNA-sequencing
on wt and rd1 retinal explants with or without DZNep
treatments (1.0 μM, P0+ 10). Consistent with previous
rd1+DZNep injected at P0
rd1+PBS
1.25μg 2.5μg 5μg
GCL
INL
ONL
GCL
INL
ONL
GCL
INL
ONL
GCL
INL
ONL
0
5
10
15
20
25
P0-P21
**
**
**
O
N
L 
Th
ic
kn
es
s (
μm
)
0
5
10
15
20
25
Harvested at
P21
**
**
*
O
N
L 
Th
ic
kn
es
s (
μm
)
GCL
INL
ONL
GCL
INL
ONL
wt+PBS wt+DZNep
(5μg)
0
20
40
60
80
wt P0-P21
PBS DZNep
O
N
L 
Th
ic
kn
es
s (
μm
) 
BA
DC
FE rd1+5μg DZNep injected
rd1+PBS
P0 P4 P8
GCL
INL
ONL
GCL
INL
ONL
GCL
INL
ONL
GCL
INL
ONL
Fig. 2 The effects of subretinal injection of DZNep on the thickness of ONL of wt and rd1 mice. a, b PBS and 5 μg DZNep were injected into
the subretinal space of wt mice at P0. The retinas were harvested at P21. Horizontal sections were stained for nuclear (DAPI, blue, a) and the ONL
thickness was measured (b). c, d PBS and indicated dosages of DZNep were injected into the subretinal space of rd1 mice at P0. The retinas were
harvested at P21. Horizontal sections were stained for nuclear (DAPI, blue, c) and the ONL thickness was measured (d). e, f PBS was injected at P0, and
5 μg DZNep was injected into the subretinal space of rd1 mice at indicated ages. The retinas were harvested at P21. Horizontal sections were stained
for nuclear (DAPI, blue, e) and the ONL thickness was measured (f). Scale bar is 50 μm. Error bars represent SD of measurements from at least three
animals and asterisks indicate signiﬁcant differences between rd1 retinas injected with PBS and DZNep of indicated dosages or ages. (*p < 0.05, **p <
0.01, one-way ANOVA followed by Bonferroni correction). ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer
Zheng et al. Cell Death and Disease  (2018) 9:310 Page 4 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
reports41, average linkage hierarchical cluster analysis
indicated that rd1 retinas clearly separated from wt reti-
nas, DZNep-treated retinas clearly separated from PBS-
treated samples, suggesting that rd1 and DZNep treat-
ment changed transcriptome signiﬁcantly (Fig. 5a). We
analyzed differentially expression genes (DEGs), and
identiﬁed 3052 genes as rd1-related DEGs (Supplemen-
tary Table 1). Gene enrichment analysis indicated that the
most enriched pathways of rd1-related DEGs included
TNF, phototransduction, focal adhesion, and PI3K-Akt
pathways (Fig. 5b). ENCODE histone modiﬁcation ana-
lysis at Enrichr indicated that the most common histone
modiﬁcation of these rd1-regulated genes is H3K27me3;
supporting H3K27me3-mediated gene silencing plays a
role in rd1 pathogenesis (Supplementary Table 2). We
identiﬁed 6062 DZNep-related DEGs, including 1634
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genes unique for wt retinas (Group Ia), 2261 genes unique
for rd1 retinas (Group IIa), and 2167 genes for both
(Fig. 5c). Among these 2167 shared genes, 131 genes were
ﬁltered to Group Ib since they had 40% more expression
changes in wt than that in rd1 retina, whereas 645 genes
were in Group IIb as they had 40% more expression
changes in rd1 retina. We then combined Group Ia and Ib
to Group I (1765 genes), and Group IIa and IIb to Group
II (2906 genes), respectively (Supplementary Table 3,
Fig. 5c), and perform pathway analysis. Interestingly, we
did not ﬁnd any enriched pathways in Group I, as all
adjusted p value > 0.05 (Supplementary Table 4), thus
consistent with our observation that 1.0 μM DZNep did
not cause any changes in wt retina (Fig. 2a).
However, we identiﬁed 17 pathways in Group II
(adjusted p < 0.05), suggesting that DZNep affects these
pathways to delay rd1 photoreceptors death. Interestingly,
11 of these 17 DZNep pathways are the same pathways
that caused rd1 phenotypes (Fig. 5b). These results indi-
cated that DZNep synergistically acts on several mole-
cular pathways that cause rd1 photoreceptor
degeneration, revealing the therapeutic potential of
DZNep for RP treatment. Heatmap of top three DZNep
pathways, including phototransduction, focal adhesion,
and PI3K-Akt pathway, were shown in Fig. 5d. We then
focused on PI3K-Akt pathway for further investigation, as
focal adhesion pathway overlaps with this pathway, and it
was reported that this survival pathway is inactivated in
rd1 retina during photoreceptor degeneration42. The PI3K
pathway is crucial to many aspects of cell adhesion, cell
growth and survival. Class I PI3Ks function as hetero-
dimers with one of four catalytic p110 subunits (p110α, β,
δ, or γ) and a regulatory subunit (p85α, p85β, p55γ, p101,
or p84)43, 44. PI3K activation leads to the production of
PIP3 which recruits Akt to the plasma membrane, where
Akt gets phosphorylated and activated on Thr308 and
Ser473 by Pdk145 and mTORC246, respectively. Pten can
antagonize PI3K action by removing the 3-phosphate
from PIP347, and Pten expression is suppressed by
NF-κB48.
RT-PCR results conﬁrmed the expression changes of
several PI3K-Akt pathway genes are consistent with RNA-
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sequencing data, such as Akt1, Bcl2, mTOR, Nfkb1, Pik3r1
(encodes p85α), Pik3r3(encodes p55γ), Pik3r5(encodes
p101), Pdpk1(encode Pdk1), and Pten (Fig. 5e). Compar-
ing to wt retinas, Akt1, Pik3r1, and Pik3r3 mRNA were
signiﬁcantly reduced in rd1 retina, while the mRNA levels
of Bcl2, mTOR, Nfkb1, Pdpk1, Pik3r5, and Pten were not
different between wt and rd1 retinas. This indicated that
reduced PI3K regulatory subunits and Akt1 expression
may contribute to the inactivation of Akt in rd1 retina42.
Consistent with the RT-PCR results (Fig. 5e), chromatin
immunoprecipitation (CHIP) found that DZNep treat-
ment signiﬁcantly reduced H3K27me3 deposition at the
promoter of Akt1, Pik3r1, and Pik3r3 genes in rd1 retina
(Fig. 5f), thus de-repressed these genes expression. The
total Akt (Akt1, Akt2, and Akt3) protein levels were
similar between wt, rd1, and rd1/DZNep retinal explants,
but its active form, phospho-Akt (Ser473), was much
reduced in rd1 retina, which was rescued by DZNep
treatment (Fig. 5g–i). This result coincided with the RNA
levels of Pik3r1, Pik3r3 (Fig. 5e), and protein level of PI3K
subunits p110α and p85α (Fig. 5g–h), indicating DZNep
treatment de-repressed PI3K subunits expression and
activated Akt in rd1 retina.
It was reported that Akt can phosphorylate Ezh2 protein
at serine 21 and suppresses its methyltransferase activity
by impeding Ezh2 binding to histone H349. Thus
H3K27me3 level is inversely correlated with Akt activity,
and explain why rd1 retina has higher H3K27me3. Indeed,
while Ezh2 protein and H3K27me3 increased in rd1
retina, phospho-Ezh2 ser21 reduced signiﬁcantly in rd1
retina comparing to wt controls (Fig. 5j–m). DZNep
treatment reduced Ezh2 expression in rd1 retina (Figs. 4a,
5j, k), but also increased the phospho-Ezh2 ser21 level,
which may result from de-repressing PI3K and activating
Akt. Consistent with this notion, PI3K inhibitor
LY294002 had opposite effects of DZNep on rd1 retina,
and thus reversed the effects of DZNep on Ezh2,
H3K27me3, and phospho-Ezh2 ser21 levels (Fig. 5j–m).
Thus Akt-mediated phosphorylation of Ezh2 at serine 21
and H3K27me3-mediated repression of PI3K subunits
expression form a negative feedback loop and this net-
work contributes to the photoreceptor survival in rd1
retina (Fig. 5n).
We also looked some genes in the phototransduction
pathway, DZNep treatment inhibit the expression of many
photoreceptor genes, such as Nrl and Nr2e3 (Fig. 5d, e),
which may also contribute to the protection effects of
DZNep on rd1 photoreceptors. Similar to this phenom-
enon, Ezh1/2 double knockout in adult striatal medium
spiny neurons (MSNs) and Purkinje cells also down-
regulated many identity genes of MSN or Purkinje cells50.
Discussion
Dysregulation of DNA methylation19 and histone acet-
ylation10, 15, 51 recently has been found to be involved in
the pathogenesis of RP. In this study, we demonstrated
that histone trimethylation also increases in rd1 mice,
suppression of Ezh2 and H3K27me3 by DZNep delays the
retinal degeneration. RNA-sequencing and Western
blotting revealed that DZNep may protect the photo-
receptors by several mechanisms including inhibiting
calpain activity, activating Akt pathway, and inhibiting
photoreceptor differentiation.
For the ﬁrst time, we found that pan-trimethyllysine of
histones signiﬁcantly increases in rd1 retina, and identi-
ﬁed 6 upregulated sites of histone H3 tri-methylation,
including H3K27, H3K36, H3.1K27, H3.1K36, H3.1K37,
and H3.1K79. In general H3K4me3, H3K79me3, and
H3K36me3 are associated with transcriptional activation,
while H3K27me3 and H3K9me3 have been linked to
transcriptional repression52. H3K37me3 can also inhibit
gene expression53. Thus rd1 retina has upregulated both
active and repressive histone methylation marks. While it
is possible that the interplay of these histone marks can
contribute to the retinal degeneration, we focused on the
role of H3K27me3 in rd1 retina in this study.
(see ﬁgure on previous page)
Fig. 5 Ezh2/H3K27me3 inhibit PI3K-Akt pathway in rd1 retina. a Cluster analysis of coding gene expression proﬁles of wt and rd1 mouse retinal
explants with or without DZNep treatments. b Gene list enrichment analysis using KEGG 2016 datasets in Enrichr of rd1-regulated and DZNep-
regulated rd1 speciﬁc DEGs (−log10(p)). Dotted line indicates p < 0.05. c Comparison of DZNep targets between wt and rd1 retinas. The genes in
Group Ia and Ib are the DZNep targets only in wt retinal cells, whereas the genes in Group IIa and IIb are the DZNep targets only in rd1 retinal cells. d
Heatmap of top 3 DZNep-regulated rd1 speciﬁc DEGs. e The relative mRNA levels of indicated DEGs and indicated treatment groups were analyzed
by RT-PCR to validate the DEGs. f Chromatin immunoprecipitation (ChIP) using H3K27me3 antibody at the promoter of indicated genes and
treatments in rd1 retinal explant cultured from P0 to P10. The enrichment of H3K27me3 was quantiﬁed using q-PCR and normalized to input. g
Representative Western blots of indicated proteins and treatments of wt and rd1 retinal explants. h The quantiﬁcation of total Akt, PI3K-P110α, PI3K-
P85α protein level relative to β-actin in g. i The quantiﬁcation of p-Akt ser473 relative to total Akt protein in g. j Representative Western blots of
indicated proteins and treatments of wt and rd1 retinal explants. k The quantiﬁcation of p-Ezh2 relative to total Ezh2 in i. l The quantiﬁcation of Ezh2
relative to β-actin in i. m. The quantiﬁcation of H3K27me3 relative to Histone H3 in i. n An integrated PI3K-Akt-Ezh2-H3K27me3 feedback loop
regulates photoreceptor survival in rd1 retina. Error bars represent SD (in h, i, k–m) or SEM (in e, f) of measurements from at least three retinal
explants and asterisks indicate signiﬁcant differences between DZNep-treated and untreated groups in e, f, or between wt and rd1 as indicated by
square brackets in e, or between rd1 group and other groups in h, i, k–m (*p < 0.05, **p < 0.01, one-way ANOVA followed by Bonferroni correction)
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H3K27me3 is a repressive chromatin mark and med-
iates epigenetic silencing, which is catalyzed by Ezh2/Eed-
containing PRC228. Mouse tissue array staining indicates
that H3K27me3 initially distribute throughout all retinal
cells at E17.5, and from P1 onward, H3K27me3 mainly
deposits in ganglion, amacrine, and horizontal cells, but
low levels of H3K27me3 can still be detected in other cell
types including rods23. These features of H3K27me3
deposition coincide with the expression pattern of Ezh2 in
mouse retina. Ezh2 is dynamically expressed during ret-
inal development, it is enriched in retinal progenitors and
downregulated in differentiated cells, by P10 Ezh2
expression is largely restricted to the ganglion cell layer
(GCL) and inner nuclear layer (INL), and then extin-
guished around P3024, 27, 31. Four studies used different
mouse Cre strains to conditionally knock out Ezh2 or Eed
in mouse retina to investigate the role of H3K27me3 in
retina24, 27, 31, 54. While knocking out Ezh2 in post-mitotic
retinal ganglion cells (RGCs) has no major phenotypes27,
inactivation of Ezh2 or Eed in retinal progenitors leads to
abnormal differentiation of late-born retinal cells (rods,
bipolar and Müller glial cells) in the early postnatal stages,
and reduced overall eye size and ONL thickness at later
postnatal stages, maybe due to reduced progenitor pool
and/or enhanced cell death24, 27, 31, 54. Thus low level of
H3K27me3 in wt progenitors may not favor the survival of
photoreceptors later.
Surprisingly, in the present study we found that
H3K27me3 increases in postnatal rd1 mouse retina. As
H3K27me3 may protect wt retinal progenitors and their
progeny, we applied HMT inhibitor DZNep to test if
H3K27me3 has a different role on the photoreceptors in
postnatal rd1 retinas. Subretinal injection of DZNep at P0
rd1 mice signiﬁcantly delayed rods death and improved
their ERG responses. These results support the notion
that elevated H3K27me3 is associated with photoreceptor
death in rd1 mice.
Similar to Ezh2 knockout in post-mitotic mouse RGCs
(but not in progenitors)27, subretinal injection of DZNep
into P0 wt retinas has no major effects on the ONL
thickness (Fig. 2a), and we did not ﬁnd any enriched
pathways of DZNep-related wt retina speciﬁc DEGs
(Supplementary Table 4). The possible reason of this
phenomenon is that in P0 wt retinas, H3K27me3 level is
already low, DZNep treatment cannot reduce the
H3K27me3 level further (Figs. 1d,4d) and induce any
observable phenotypes.
It is intriguing that H3K27me3 has opposite effects on
wt retinal progenitors and postnatal rd1 photoreceptors,
but similar phenomenon was reported in a number of
studies. For instance, knocking out PRC1 component
Bmi1 in wt mice causes degeneration of cone photo-
receptors55, but knocking out Bmi1 in rd1 mice strongly
delays the rod degeneration25. Knocking out Ezh1/2 in
MSNs and Purkinje cells lead to progressive neurode-
generation in wt mice50, but inhibiting Ezh2 rescued
Purkinje cell degeneration in Atm−/− mice32. Thus Ezh2
or H3K27me3 is important both for normal development
and pathogenesis of neurodegeneration, and maintain the
homeostasis of H3K27me is closely related to the survival
of photoreceptor and other neurons.
To understand why H3K27me3 increases and how
DZNep protects rd1 photoreceptors, we used an ex vivo
retinal explant system, which can represent the in vivo rd1
pathogenesis in several previous studies10, 19. Although
DZNep may be a global inhibitor of methyltransferases37,
and can suppress H3K9me3 and H3K79me3 formation in
several cancer cell types38, 39, we had not found any effects
of DZNep on H3K9me3 and H3K79me3 in our ex vivo
retinal explant system. Thus DZNep can protect rd1
retina by suppressing calpain activity and H3K27me3
deposition, but not H3K9me3 or H3K79me3. RNA-
sequencing and transcriptome analysis revealed that the
protective effect of DZNep in rd1 may be associated with
Akt pathway and photoreceptor differentiation.
Ezh2 is the core component of PRC2, and its HMT
enzyme activity is modulated by several kinases, including
Akt, Atm, Cdk1, and Cdk2. While Cdk2-mediated Ezh2
phosphorylation on Thr350 increases H3K27 methyla-
tion56, Ezh2 phosphorylation on Ser21 by Akt49, or Ser734
by Atm32, or Thr487 by Cdk157 prevent it. We conﬁrmed
previous study that PI3K-Akt pathway is inactivated in
rd1 retinal explants42, as phospho-Akt ser473 signiﬁcantly
reduced. Reduced Akt activity results in reduced
phospho-Ezh2 ser21, enhanced PRC2 activity, and high
levels of H3K27me3 in rd1 retina. PI3K inhibitor
LY294002 has opposite effects of DZNep on rd1 retinas.
Thus PI3K-Akt pathway and H3K27me3 forms a feedback
loop in rd1 retina (Fig. 5g–n). Our result in rd1 mice is
similar to the Atm−/− mice, an animal model of ataxia-
telangiectasia and cerebellum neurodegeneration32.
H3K27me3 elevated in Atm−/− mice due to reduced
phospho-Ezh2 ser734. Lentiviral knockdown Ezh2 res-
cued Purkinje cell degeneration and behavioral abnorm-
alities in Atm−/− mice32. Thus PRC2 hyperactivity may be
a common mechanism to induce neurodegeneration, and
a new therapeutic target for RP treatment, and need to be
further explored in the future.
We also found that DZNep downregulated many pho-
toreceptor genes such as Nrl and Nr2e3 (Fig. 5e), similar
to the Ezh1/2 mutant striatal MSNs and Purkinje cells,
which also downregulated many identity genes of MSN or
Purkinje neurons50. Likely dysregulation of these neuronal
identity genes is secondary to the over-expression of some
direct PRC2 targets, but the exact mechanism is still
unknown58. Nrl acts as a cell fate switch during retinal
development, photoreceptor precursors that turn on Nrl
become rods, whereas those that do not become cones59.
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Targeted inactivation of Nrl via CRISPR/Cas9-mediated
genome editing can rescue retinal rod and cone degen-
eration and restore visual function in four different mouse
RP models (rd1, rd10, Rho−/−, RHOP347S)60, 61. Thus
DZNep may protect rod photoreceptor by down-
regulation of Nrl and its downstream target Nr2e3.
In summary, we found that rd1 retina has high levels
trimethylation of several lysine sites of histone H3,
including lysine 27 (H3K27me3), downregulating
H3K27me3 with PRC2 inhibitor DZNep can delay the
photoreceptor degeneration in rd1 mice, which is related
with multiple signaling pathways, including PI3K-Akt and
rod differentiation pathways. To our knowledge, this is
the ﬁrst report that elevated H3K27me3 histone mark is
involved in the pathogenesis of rd1 retinal degeneration,
and is a potential therapeutic target for RP treatment.
Materials and methods
Animals
The Pde6brd1 (rd1) mice on ICR background were
purchased from Taconic (Germantown, NY, USA) and
housed in the Laboratory Animal Center of Sichuan
University (Chengdu, China) with a normal 12-h/12-h
light/dark schedule. Fresh water and rodent diet were
available at all times. Age-matched wt ICR mice were
used as control. All animal procedures were performed
in accordance with the statement of the Association for
Research in Vision and Ophthalmology (ARVO), and
the protocol was approved by Ethics Committee of
Animal Research of West China Hospital, Sichuan
University.
Ex vivo retinal explant cultures and DZNep or LY294002
treatment
Retinal explants obtained from newborn rd1 and wt
mice were cultured using a protocol from previously
described methods10, 19, 62. Brieﬂy, both eyes were enu-
cleated and retinas were carefully peeled away from the
retinal pigment epithelium, and radial cuts were made to
ﬂatten the retina. The ﬂattened retina was transferred to
the membrane of a Millicell insert (Millipore,
PICM03050) with the photoreceptors facing down. The
insert was placed into the wells of a 6-well plate (Costar
3516, Corning), each contained 1300 μl of retinal explant
media, which was replaced every 2 days, and was main-
tained in a 37 °C incubator with 5% CO2 for 10 days. The
retinal explant basal medium was serum-free and made
from Neurobasal A, DMEM/F12 medium, and N2/
B27 supplements (Life Technologies, USA). Cultured
explants were either exposed to DZNep (Cayman Che-
mical, 13828, Ann Arbor, USA) treatment (0.1 μM, 0.5
μM, 1 μM, 1.5 μM), LY294002 (Selleckchem, S1105,
Houston, TX, USA) treatment (20 μM), or kept as PBS-
treated controls.
Western blotting
Total Histones or protein were extracted from retinas as
well as retinal explants using the total histone extraction
kit (Epigentek, Farmingdale, NY, USA) or RIPA lysis
buffer containing 1% proteases inhibitor and phosphatase
inhibitors (Beyotime Institute of Biotechnology, Haimen,
China) according to the manufacturer’s instructions. The
protein concentration was determined with a bicincho-
ninic acid (BCA) assay kit (Beyotime). Then, 30 μg pro-
teins was separated by 15% or 12% SDS-polyacrylamide
gel and the separated proteins were transferred to poly-
vinylidene diﬂuoride membranes (Millipore, Billerica,
MA, USA). After blocking with 5% non-fat milk or 5%
bovine serum albumin, the membranes were incubated
with primary antibodies against Akt (1:1000, Cell Signal-
ing Technology, 9272, Beverly, MA, USA), Phospho-Akt
(Ser473) (1:1000, Cell Signaling Technology, 4058, Bev-
erly, MA, USA), Ezh2 (1:1000, Cell Signaling Technology,
3147, Beverly, MA, USA), Phospho-Ezh2 (Ser21) (1:200,
Abcam, ab84989, Cambridge, MA), H3K27me3 (1:1000,
Cell Signaling Technology, Beverly, 9733, MA, USA),
H3K9me3 (1:500, Millipore, 07-442, Billerica, MA, USA),
H3K79me3 (1:1000, Abcam, ab2621, Cambridge, MA),
Histone H3 (1:2000, Cell Signaling Technology, 4499,
Beverly, MA, USA), Pan-trimethyllysine (1:1000, PTM-
Biolabs, PTM-601, Hangzhou, China), PI3K p110α
(1:1000, Cell Signaling Technology, 4249, Beverly, MA,
USA), PI3K p85α (1:1000, Cell Signaling Technology,
13666, Beverly, MA, USA), and β-actin (1:2000; Abcam,
ab6276, Cambridge, MA). After washing, the membrane
was incubated with secondary antibody for 1 h. The
images were captured on the Odyssey CLx Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
Western blotting bands were quantiﬁed using Odyssey
CLx v2.1 software and normalizing to histone H3
(H3K27me3, H3K9me3, H3M29me3) or β-actin (Akt,
Ezh2, PI3K p110α, PI3K p85α) as loading control, or Akt
(pAkt ser473), and Ezh2 (p-Ezh2 ser 21).
Quantiﬁcation of histone lysine trimethylation
The quantiﬁcation of histone lysine trimethylation in
retinas were performed by PTM Biolabs (Hangzhou,
China) with integrated approach involving TMT labeling,
HPLC fractionation, lysine trimethylation afﬁnity enrich-
ment, mass spectrometry-based quantitative histone to
quantify dynamic changes. Brieﬂy, total histone was ﬁrst
extracted from retinas. After trypsin digestion, peptide
was reconstituted in 0.5M TEAB and processed accord-
ing to the manufacturer’s protocol for 6-plex TMT kit
(Thermo Scientiﬁc, Rockford, IL, USA). The sample was
then fractionated into fractions by high pH reverse-phase
HPLC using Agilent 300 Extend C18 column (5 μm par-
ticles, 4.6 mm ID, 250mm length). To enrich lysine tri-
methylation peptides, tryptic peptides dissolved in NETN
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buffer were incubated with pre-washed antibody beads
(PTM Biolabs) at 4 °C overnight with gentle shaking, and
then washed and vacuum-dried. The resulting peptides
were cleaned with C18 ZipTips (Millipore) according to
the manufacturer’s instructions, followed by LC-MS/MS
analysis by Q Exactive TMPlus hybrid quadrupole Orbi-
trap mass spectrometer (Thermo Fisher Scientiﬁc). The
resulting MS/MS data was processed using MaxQuant
with integrated Andromeda search engine (v.1.4.1.2).
Tandem mass spectra were searched against UniProt
mouse Histone database concatenated with reverse decoy
database. Trypsin/P was speciﬁed as cleavage enzyme
allowing up to 3 missing cleavages, 4 modiﬁcations per
peptide, and 5 charges. Mass error was set to 10 ppm for
precursor ions and 0.02 Da for fragment ions. Carbami-
domethylation on Cys was speciﬁed as ﬁxed modiﬁcation
and oxidation on Met, trimethylation on Lys, and acet-
ylation on protein N-terminal were speciﬁed as variable
modiﬁcations. False discovery rate (FDR) thresholds for
protein, peptide, and modiﬁcation site were speciﬁed at
1%. Minimum peptide length was set at 7. All the other
parameters in MaxQuant were set to default values. The
site localization probability was set as >0.75.
Quantiﬁcation of global tri-methyl histone H3K27
Total histones were extracted from retina of postnatal
day 0 (P0) and P10 mice, as well as retinal explants using
the total histone extraction kit (Epigentek, Farmingdale,
NY, USA) according to the manufacturer’s Instructions.
Quantiﬁcation of trimethylated H3K27 was performed
using the EpiQuik global tri-methyl histone H3-K27
quantiﬁcation kit (Colorimetric). The optical density value
of histone lysine methylation at 450 nm was normalized to
the standard control protein. The amount of trimethy-
lated H3K27 were calculated applying the following for-
mulas: Amount (ng/mg protein)= (OD (sample−blank)/
protein (μg) × slope) × 1000.
Calpain activity assay
Calpain activity was measured with a Calpain Activity
Assay kit (Biovision, Mountain View, CA) according to
the instructions of the manufacturer. Retinas were col-
lected from P0, P10 mice, and retinal explants. Detection
of the cleavage substrate Ac-LLY-AFC was performed in a
ﬂuorometer (Perkin Elmer, Inc., Waltham, MA, USA) that
was equipped with a 400-nm excitation ﬁlter and 505-nm
emission ﬁlter.
Subretinal injection of DZNep
One microliter of DZNep (1.25 μg/μl, 2.5 μg/μl, 5 μg/μl)
in PBS (Cayman 13828, Ann Arbor, MI, USA) was
injected into the subretinal space of one eye according to
a method described previously63. The same volume of
PBS was administrated as control. Brieﬂy, newborn (P0),
P4, and P8 rd1 and ICR wt mouse pups were anesthetized
by chilling on ice or anesthetized with the mixture of
ketamine and xylazine, and a small incision was made in
the eyelid with a 32-gauge needle to expose the eyeball. A
small hole was made through the limbus with a 32-gauge
needle, and then a blunt 33-gauge needle (Hamilton syr-
inge) was inserted through the hole, avoiding damage to
the lens and penetrating the retina under a dissecting
microscope. The successful delivery of drug was con-
ﬁrmed by viewing ﬂuorescein-positive subretinal blebs
demarcating the retinal detachment in the injected retinal
area. Such detachments usually can be resolved sponta-
neously within 1 to 2 days. All animals received antibiotic
ointment to the conjunctival sac and were observed daily
after operation.
Histology immunostaining
Immunoﬂuorescence was performed using previously
described protocols64. Brieﬂy, eyeballs were collected at
P14 and P21 after DZNep injection, and were ﬁxed by 4%
paraformaldehyde in 0.1M phosphate buffer saline (PBS,
pH 7.4) at 4 °C for 60min, dehydrated in 30% sucrose
overnight, and frozen in OCT at −80 °C. Cryostat sections
were cut at 5 μm and collected on glass slides and stored
at −20 °C. For immunostaining, the retinal sections were
dried at room temperature (RT) and incubated in block-
ing solution (5% normal donkey serum, 1% BSA, and
0.03% Triton X-100 in 1× PBS) for 1 h, then were incu-
bated with primary antibodies (Rhodopsin 1:1000, Santa
Cruz, SC-57433) at 4 °C overnight. Subsequently, slides
were incubated with corresponding secondary antibodies,
conjugated to Alexa Fluor 488 (Invitrogen, USA), for 1 h
at RT in the dark. Finally, slides were counterstained with
4′6-diamidino-2-phenylindole (DAPI; Sigma Aldrich
Corp.) and mounted with Mowiol mounting medium. The
thickness of ONL was measured in four areas at a distance
of 500–1000 μm from the edge of optic disc. At least four
sections of each eye were measured and data from four
sections were averaged for each eye.
TUNEL staining
To determine whether cell death had occurred, the
frozen sections of mice eyes with or without DZNep
treatment at P14 and P21 were labeled by TdT-dUTP
terminal nick-end labeling (TUNEL) with an apoptosis
detection kit (In Situ Cell Death Detection Kit; Roche
Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions. Non-speciﬁc signals were
detected by omission of the enzyme reaction. Stained
sections and slides were analyzed using a Zeiss Axio
Imager Z2 ﬂuorescence microscope, and Nikon A1RMP
confocal microscope. Image J 1.50b with cell counter
plugin was used for cell counting following the online
guide. The positive cells of TUNEL were counted
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manually. At least 2 images per section, 2 sections per
retina, and 3 retinas from each group were counted. All
images for cell-counting were captured under ﬂuores-
cence microscope using a 20× objective lens.
Electroretinogram (ERG)
Both dark- and light-adapted ERG (Diagnosys LLC,
Lowell, MA) were recorded at the 14th and 21th day after
DZNep treatment. The procedures were performed as
previous described64. In brief, mice were dark-adapted
overnight and anesthetized with the mixture of ketamine
and xylazine, and pupils were dilated with 0.5% tropica-
mide and 0.5% phenylephrine hydrochloride. Full-ﬁeld
ERG was recorded after inserting a ground electrode near
the tail and a reference electrode on the back sub-
cutaneously. A golden-ring electrode was gently posi-
tioned on the cornea. All procedures were performed
under dim red light. The amplitude of the a-wave was
measured from the baseline to the peak of a-wave, and the
b-wave was measured from the nadir of the a-wave to the
apex of the b-wave peak.
RNA-sequencing
Total RNAs were extracted from retinal explants using
TRIzol reagents (Invitrogen, Carlsbad, CA) and treated
with RNase-free DNase I (New England Biolabs, Beverly,
MA) to remove genomic DNA. The yield of total RNA
was assessed using Nanodrop (Thermo). The cDNA
libraries were prepared using the Illumina TruSeq RNA
sample preparation kit and the qualities were assessed
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). For sequencing, the cDNA libraries were
loaded on an Illumina HiSeq 2500 at Biomaker (Beijing,
China). The raw sequence reads in fastq format were
processed and analyzed as previously reported65, 66.
Brieﬂy, the sequencing quality was ﬁrst assessed using
FastQC and poor quality 5′ end reads were trimmed
using a Perl script and then mapped onto mouse genome
(mm9) using Tophat2, allowing for up to two mismatches
as default settings. Reads were mapped onto multiple
genomic locations were discarded and a custom R script
was used to calculate the RPKM of each gene and obtain
expression proﬁle of each sample. The expression fold
change of each coding gene of rd1 retina compared to wt
retina was calculated using the following formula: Fold
change= (RPKM+ 1)rd1 / (RPKM+ 1)wt. The genes, of
which expression fold changes are >1.54 or <0.65, were
selected as the rd1-related DEGs. The expression fold
change of each coding gene after DZNep treatment was
calculated using the following formula: Fold change=
(RPKM+ 1)+DZNep / (RPKM+ 1)−DZNep. The genes, of
which expression fold changes are >1.54 or <0.65 upon
drug treatment, were selected as the DZNep-related
DEG. The function enrichment of DEG was performed
using Enrichr67, 68, the pathways with adjusted p < 0.05
were chosen to report. The heatmap was generated using
the R package of gplots and polished using Adobe
Illustrator.
Table 2 Sequences of primers for real-time PCR
Gene Forward primer Reverse primer
Akt1 5′−CACGGATACCATGAACGACG-3' 5′−GTTCTTGAGGAGGAAGTAGCGT−3′
Akt1 promoter (ChIP) 5′−GAAGAGCATCCGAGTGAGAAG−3′ 5′−CTACACAGTTAGAGCCAGCAGG−3′
Bcl-2 5′−TGGGATGCCTTTGTGGAACTAT−3′ 5′−AGAGACAGCCAGGAGAAATCAAAC−3′
GAPDH 5′−GCAAGGACACTGAGCAAGAGA−3′ 5′−ATTCAAGAGAGTAGGGAGGGCT−3′
mTOR 5′−GAGAGGCTATCCGAGTGTTG−3′ 5′−TGACTTGACTTGGACTCTGACA−3′
Nfkb1 5′−CAGAAAGATGACATCCAGAT−3′ 5′−CAATGGCAAACTGTCTATGAAC−3′
Nr2e3 5′−GGTTGGGCCCAGCAACTTCT−3′ 5′−CGCCACAGACACAGGCATAG−3′
Nrl 5′−GCTGCATTTTCACCGAATCT−3′ 5′−GGTGGTTTGGGTTGTGGTAG−3′
Pdpk1 5′−CTGTGAAGAGATGGAAGGGTA−3′ 5′−ATTGTCGTAGTTGCCATAGCA−3′
PIK3R1 5′−ACAGTAGGAGGAGGTTGGAAGA−3′ 5′−TGCGTCAGCCACATCAAGTAT−3′
PIK3R1 promoter (ChIP) 5′−TGTGATGTGGGTAGCAGCCT−3′ 5′−TGTGAGTTTTGGAAGCAGAGG−3′
PIk3R3 5′−AAGGACATCACAGGAAATACAA−3′ 5′−ACTGTGTTGTTCTTGGGTATGA−3′
PIK3R3 promoter (ChIP) 5′−GACGATGGGGATCTTGTCTG−3′ 5′−TCCTCACAAACCTCTTCACCT−3′
PIK3R5 5′−ACCCAAGAGGTCCAAGAGAA−3′ 5′−CAGGAGGTCGGAGTCTGGTG−3′
PTEN 5′−CTTCCACAAACAGAACAAGATG−3′ 5′−GCTCTATACTGCAAATGCTATC−3′
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RNA extraction, reverse transcription, and quantitative
real-time PCR
Total RNA was extracted from retinal explants using
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. After quantifying by a
Nanodrop Spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA), cDNA was synthesized from 1 μg
total RNA with PrimeScript RT reagent kit (Takara Bio-
technology, Dalian, China). To quantify the cDNA, real-
time PCR was performed on qTOWER 2.2 system (Ana-
lytik Jena, German). The PCR ampliﬁcation was con-
ducted in a volume of 20 μl using SsoFastTMEvaGreen®
Supermix (Bio-Rad Laboratories Inc., Hercules, CA,
USA). The cycling protocol consisted of one cycle of 10
min at 95 °C followed by 40 cycles of 95 °C for 15 s and 60
°C for 1 min. To determine the mRNA expression, all
samples were tested in duplicate and the average Ct values
were used for quantiﬁcation. The mRNA expression was
normalized to the endogenous reference gene, glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). Relative
quantiﬁcation was achieved by using the 2−ΔΔCt method
as described previously64. Ampliﬁcation of speciﬁc tran-
scripts was conﬁrmed by melting curve proﬁles at the end
of each PCR. The primers sequences are listed in the
Table 2.
Chromatin immunoprecipitation (ChIP)
The ChIP assay was performed using Magna ChIPTM
A/G Chromatin Immunoprecipitation Kit (Millipore
Temecula, CA, USA) according to the manufacturer’s
instructions. Brieﬂy, retinal explants treated with or
without DZNep were cut into small pieces and then cross-
linked for 10–20min by addition of formaldehyde to a
ﬁnal concentration of 1%. The cross-linking was stopped
by adding 1/20 volume of 2.5M glycine and lysed by SDS
lysis buffer. Then cell lysate was sonicated and immuno-
precipitated with antibodies speciﬁc to H3K27me3 (1:50,
Cell Signaling Technology, 9733) or negative control IgG.
After protein/DNA complexes were eluted, reverse cross-
linked to free DNA and puriﬁed, the speciﬁc DNA frag-
ments were quantiﬁed using real-time PCR and normal-
ized to input from the same sample. The primer
sequences for the promoters analyzed are provided in
Table 2.
Statistical analysis
All experiments were carried out with n= 3–15. Sta-
tistical analysis was undertaken using the GraphPad Prism
software (GraphPad Prism Software, Inc., San Diego, CA,
USA). The results were analyzed by one-way ANOVA
followed by Bonferroni correction for multiple compar-
isons, unpaired Student’s t-test was used to assess sig-
niﬁcance between two groups. The threshold for
signiﬁcance was set at p < 0.05.
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